Regorafenib is also a potent UGTs inhibitor, which is consistent with the hypothesis that inhibition of UGT1A1 is involved in the hyperbilirubinemia observed in patients treated with this drug [51]. Here, UGT1A1 is linked to Hyperbilirubinemia.